Veru Inc
Veru Inc (NASDAQ: VERU) is a clinical-stage biopharmaceutical company with a market capitalisation of about $63.03 million. The business focuses on developing therapies in oncology, infectious disease and supportive care, with progress largely tied to its clinical pipeline, trial readouts and regulatory decisions. As a small-cap, research-driven company, revenue can be limited and financing, partnerships or licensing deals often matter as much as clinical data. Shares tend to be volatile around trial milestones and news flow. For investors, key considerations include the stage and size of ongoing studies, cash runway, management’s strategy for commercialisation or partnerships, and the regulatory environment. This overview is for general educational purposes only and is not personalised investment advice. Biotech stocks can carry high risk and substantial price swings; potential investors should carry out their own research or consult a regulated financial adviser about suitability.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Veru's stock with a target price of $3.44, indicating strong potential growth.
Financial Health
Veru Inc has modest revenue and cash flow, with some concerns about profitability and asset value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring VERU
New Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical trial readouts and regulatory milestones can create meaningful share-price movement, though outcomes are uncertain and can be binary.
Small-cap Volatility Profile
With a market cap around $63M, liquidity and news sensitivity are higher; investors should expect significant price swings and funding risk.
Partnerships and Funding
Strategic collaborations or financing rounds can materially affect development progress and valuation, but such events are not guaranteed.
Compare Veru with other stocks
Grove Collaborative vs Veru
Grove Collaborative vs Veru
PetMed Express vs Veru
PetMed Express vs Veru Inc
Laird Superfood vs Veru
Laird Superfood vs Veru
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Colgate-Palmolive Co.
Colgate-Palmolive Company is a growth company. It is focused on Oral Care, Personal Care, Home Care and Pet Nutrition, it sells its products under brands, such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet. Its Oral, Personal and Home Care product segment is managed geographically in five segments, such as North America, Latin America, Europe, Asia Pacific and Africa/Eurasia, all of which sell primarily to a variety of traditional and e-commerce retailers, wholesalers, distributors, dentists and skin health professionals. Its Pet Nutrition products include specialty pet nutrition products manufactured and marketed by Hill's Pet Nutrition. The customers for Pet Nutrition products are authorized pet supply retailers, veterinarians and e-commerce retailers.
Estée Lauder Companies Inc.
Estee Lauder manufactures and markets personal care, fragrance, and cosmetics products worldwide
Church & Dwight Co. Inc.
Manufacturer of household and personal care products
